Log in

Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA)

$59.03
+0.75 (+1.29 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$58.90
Now: $59.03
$61.40
50-Day Range
$57.28
MA: $66.75
$72.73
52-Week Range
$57.15
Now: $59.03
$106.80
Volume168,142 shs
Average Volume255,190 shs
Market Capitalization$1.16 billion
P/E Ratio16.96
Dividend YieldN/A
Beta0.93
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.63 million
Cash Flow$3.85 per share
Book Value$20.32 per share

Profitability

Net Income$71.95 million

Miscellaneous

Employees113
Market Cap$1.16 billion
Next Earnings Date11/25/2019 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.27. The biotechnology company had revenue of $44.40 million for the quarter, compared to the consensus estimate of $46.98 million. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. Enanta Pharmaceuticals's revenue for the quarter was down 22.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

4 brokerages have issued 1-year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.00 in the next twelve months. This suggests a possible upside of 71.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News coverage about ENTA stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Enanta Pharmaceuticals.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,230,300 shares, an increase of 15.7% from the July 31st total of 1,928,200 shares. Based on an average daily volume of 192,500 shares, the short-interest ratio is presently 11.6 days. Approximately 14.1% of the shares of the company are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), NVIDIA (NVDA), Alibaba Group (BABA), Tandem Diabetes Care (TNDM), Micron Technology (MU), Tesla (TSLA) and Netflix (NFLX).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%), Pacer Advisors Inc. (0.03%) and Advantage Investment Management LLC (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Advantage Investment Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Pacer Advisors Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $59.03.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.16 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel